POINT Biopharma Global, Inc. (PNT)
|Net Income (ttm)||-27.94M|
|Day's Range||7.68 - 8.09|
|52-Week Range||6.64 - 18.08|
|Est. Earnings Date||Nov 12, 2021|
POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, ... [Read more...]
ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imagi...
BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world's most needed medical radioi...
Point Biopharma Global Inc (NASDAQ: PNT) has additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program, PNT2004. The new data demonstrate rapid and persiste...
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models
Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in com...
CAMBRIDGE, Mass. and INDIANAPOLIS, Sept.
NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Ac...
BELOIT, Wis. & INDIANAPOLIS--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and POINT Biopharma have signed a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).
INDIANAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changin...
Strengthened the Company's balance sheet by completing the business combination with Therapeutics Acquisition Corp (“RACA”), with gross proceeds from the transaction totaling approximately $286.7 million
Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT
BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4...
INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, ...
INDIANAPOLIS--(BUSINESS WIRE)--POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today th...
Australis Capital completes first phase of Green Therapeutics acquisition with cannabis subsidiary purchase
Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) (FRA:AC4) announced Wednesday that it has completed the first stage of its previously announced acquisition of Nevada cannabis company Green Therapeutics LLC...
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has exercised the option to acquire Maverick Therapeutics, following an agreement signed in 2017, in which Takeda received an equity stake and an exclusive right...
These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?
BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp. (Nasdaq: TXAC) (the "Company") announced today that on July 10, 2020 it closed its initial public offering of 13,570,000 shares of Class A...
The special purpose acquisition company is sponsored by RA Capital Management.